[Therapy of recurrent and metastatic squamous cell carcinoma of the head and neck : highlights of the ASCO Meeting 2013].
In many cases squamous cell carcinoma of the head and neck is already in an advanced stage when initially diagnosed. Despite definitive treatment, loco-regional recurrences and metastases are common and patients ultimately require systemic treatment. Epidermal growth factor receptor (EGFR) inhibitors have proven to significantly prolong survival and have therefore become the first line treatment in recurrent and metastatic squamous cell carcinoma of the head and neck in addition to platinum and 5-FU treatment. Good results have also been reported for EGFR inhibitors in cases where platinum-based treatment has failed. Further strategies, such as salvage surgery, platinum-based chemotherapy, targeted therapy, chemoradiation and reirradiation are currently under investigation to reduce toxicity and improve survival and health-related quality of life.
Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Kopf-Hals-Tumorzentrum des Universitären Cancer Center Hamburg, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland.
M
M
Hezel
T
T
Kurzweg
A
A
Münscher
P
P
Schafhausen
R
R
Knecht
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D059248:Chemoradiotherapy / Q000379:methods*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D019317:Evidence-Based Medicine; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D000077195:Squamous Cell Carcinoma of Head and Neck; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D066246:ErbB Receptors